SLDB
|Solid Biosciences LLC
NASDAQ
USD 4.61
-0.22|-4.55%
Current Price
USD 4.61
Change
USD -0.22 (-4.55%)
P/E Ratio
Dividend Yield
Market Cap
329.44M
Volume
1.61M
Open
USD 4.90
Previous Close
USD 4.83
52-Week High
USD 10.37
52-Week Low
USD 2.41
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopath...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Alexander G. Cumbo
Employees:100
Headquarters:Charlestown, USA
Website:www.solidbio.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions